01 abril 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Radial Versus Femoral Access for Coronary Angiography/Intervention in Women With Acute Coronary Syndromes. Insights From the RIVAL Trial (Radial Vs femorAL access for coronary intervention)

Shaheen Pandie, MB ChB, MMed∗; Shamir R. Mehta, MD, MSc∗; Warren J. Cantor, MD†; Asim N. Cheema, MD, PhD‡; Peggy Gao, MSc∗; Mina Madan, MD§; Kari Niemela, MD, PhD‖; Sunil V. Rao, MD¶; Jon David Schwalm, MD∗; Vicent Valentin, MD#; James L. Velianou, MD∗; Sanjit S. Jolly, MD, MSc∗

Objectives: The purpose of this study was to determine the efficacy and safety of radial versus femoral access in women undergoing coronary angiography/intervention.

01 noviembre 2014

JACC. Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. The SECURITY Randomized Clinical Trial

Antonio Colombo, MD∗; Alaide Chieffo, MD∗; Arian Frasheri, MD†; Roberto Garbo, MD‡; Monica Masotti-Centol, MD§; Neus Salvatella, MD‖; Juan Francisco Oteo Dominguez, MD¶; Luigi Steffanon, MD#; Giuseppe Tarantini, MD∗∗; Patrizia Presbitero, MD††; Alberto Menozzi, MD‡‡; Edoardo Pucci, MD§§; Josepa Mauri, MD‖‖; Bruno Mario Cesana, MD¶¶; Gennaro Giustino, MD∗; Gennaro Sardella, MD##

Background: The optimal duration of dual antiplatelet therapy (DAPT) following second-generation drug-eluting stent (DES) implantation is still debated.

01 diciembre 2014

JACC. Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation. The ARREST-AF Cohort Study

Rajeev K. Pathak, MBBS∗; Melissa E. Middeldorp∗; Dennis H. Lau, MBBS, PhD∗; Abhinav B. Mehta, MActSt†; Rajiv Mahajan, MD∗; Darragh Twomey, MBBS∗; Muayad Alasady, MBBS∗,†; Lorraine Hanley, BSc∗; Nicholas A. Antic, MBBS, PhD‡; R. Doug McEvoy, MBBS, MD‡; Jonathan M. Kalman, MBBS, PhD§; Walter P. Abhayaratna, MBBS, PhD‖; Prashanthan Sanders, MBBS, PhD∗

Background: The long-term outcome of atrial fibrillation (AF) ablation demonstrates attrition. This outcome may be due to failure to attenuate the progressive substrate promoted by cardiovascular risk factors.

01 diciembre 2014

JACC. Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve

John Webb, MD∗; Gino Gerosa, MD†; Thierry Lefèvre, MD‡; Jonathon Leipsic, MD∗; Mark Spence, MD§; Martyn Thomas, MD‖; Matthias Thielmann, MD¶; Hendrik Treede, MD#; Olaf Wendler, MD∗∗; Thomas Walther, MD††

Background: The SAPIEN 3 (Edwards Lifesciences Inc., Irvine, California) transcatheter valve incorporates features designed to address the well-known deficiencies of transcatheter aortic valve replacement (TAVR). An ultra–low-profile delivery system facilitates safe, controlled, and accurate implantation and an external seal minimizes paravalvular regurgitation.

01 diciembre 2014

JACC. Coronary Stent Thrombosis With Vorapaxar Versus Placebo. Results From the TRA 2°P-TIMI 50 Trial

Marc P. Bonaca, MD, MPH; Benjamin M. Scirica, MD, MPH; Eugene Braunwald, MD; Stephen D. Wiviott, MD; Michelle L. O´Donoghue, MD, MPH; Sabina A. Murphy, MPH; David A. Morrow, MD, MPH

Background: Vorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease.

01 diciembre 2014

JACC. Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Disease

Background: Limited information exists describing the results of transcatheter aortic valve (TAV) replacement in patients with bicuspid aortic valve (BAV) disease (TAV-in-BAV).

01 diciembre 2014

JACC. OCT Assessment of the Long-Term Vascular Healing Response 5 Years After Everolimus-Eluting Bioresorbable Vascular Scaffold

Antonios Karanasos, MD∗; Cihan Simsek, MD∗; Muthukarrupan Gnanadesigan, MSc†; Nienke S. van Ditzhuijzen, MSc∗; Raphael Freire, MD∗; Jouke Dijkstra, PhD‡; Shengxian Tu, PhD‡; Nicolas Van Mieghem, MD∗; Gijs van Soest, PhD†; Peter de Jaegere, MD, PhD∗; Patrick W. Serruys, MD, PhD∗; Felix Zijlstra, MD, PhD∗; Robert-Jan van Geuns, MD, PhD∗; Evelyn Regar, MD, PhD∗

Background: Although recent observations suggest a favorable initial healing process of the everolimus-eluting bioresorbable vascular scaffold (BVS), little is known regarding long-term healing response.

01 diciembre 2014

JACC. Comparison of Radiofrequency Catheter Ablation of Drivers and Circumferential Pulmonary Vein Isolation in Atrial Fibrillation. A Noninferiority Randomized Multicenter RADAR-AF Trial

Felipe Atienza, MD, PhD∗; Jesús Almendral, MD, PhD†; José Miguel Ormaetxe, MD, PhD‡; Ángel Moya, MD§; Jesús Daniel Martínez-Alday, MD, PhD‖; Antonio Hernández-Madrid, MD, PhD¶; Eduardo Castellanos, MD#; Fernando Arribas, MD, PhD∗∗; Miguel Ángel Arias, MD, PhD#; Luis Tercedor, MD††; Rafael Peinado, MD, PhD‡‡; Maria Fe Arcocha, MD‡; Mercedes Ortiz, PhD†; Nieves Martínez-Alzamora, PhD§§; Ángel Arenal, MD, PhD∗; Francisco Fernández-Avilés, MD, PhD∗; José Jalife, MD‖‖

Background: Empiric circumferential pulmonary vein isolation (CPVI) has become the therapy of choice for drug-refractory atrial fibrillation (AF). Although results are suboptimal, it is unknown whether mechanistically-based strategies targeting AF drivers are superior.

01 diciembre 2014

JACC. The Incremental Risk of Noncardiac Surgery on Adverse Cardiac Events Following Coronary Stenting

Carla N. Holcomb, MD∗; Laura A. Graham, MPH†; Joshua S. Richman, MD, PhD∗; Robert R. Rhyne, BS∗; Kamal M.F. Itani, MD‡; Thomas M. Maddox, MD, MSc§; Mary T. Hawn, MD, MPH∗

Background: Recent coronary stent placement and noncardiac surgery contribute to the risk of adverse cardiac events, but the relative contributions of these two factors have not been quantified.

01 febrero 2015

JACC. Impact of Classic and Paradoxical Low Flow on Survival After Aortic Valve Replacement for Severe Aortic Stenosis

Marie-Annick Clavel, DVM, PhD; Maxime Berthelot-Richer, MD; Florent Le Ven, MD, MSc; Romain Capoulade, PhD; Abdellaziz Dahou, MD, MSc; Jean G. Dumesnil, MD; Patrick Mathieu, MD; Philippe Pibarot, DVM, PhD

Background: Low flow (LF) can occur with reduced (classic) or preserved (paradoxical) left ventricular ejection fraction (LVEF).

01 febrero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Use of local anesthetic (0.25% bupivacaine) for pain control after pediatric cardiac catheterization: A randomized controlled trial

Amy Palma RN, Jacqueline Viegas RN, Cedric Manlhiot BSc, Brian McCrindle MD, FACC, FRCPC andLee Benson MD, FRCPC, FACC, FSCAI*

Objectives: To investigate the effects of local infiltration of 0.25% bupivacaine on post-operative pain and analgesic use in children undergoing cardiac catheterization procedures.

01 enero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies

Marco Zimarino MD, PhD1,*, Fabrizio Ricci MD1, Mattia Romanello MD1, Marta Di Nicola PhD2, Alessandro Corazzini MD1 andRaffaele De Caterina MD, PhD1

Objectives: To test whether a strategy of complete revascularization (CR) as compared with incomplete myocardial revascularization (IR)—both performed with current “state-of-the-art” percutaneous coronary interventions (PCI) or coronary artery bypass graft (CABG)—would provide a clinical benefit in patients with multivessel coronary artery disease (MVCAD).

01 enero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions

Francesco Burzotta MD, PhD1,*, Francesco Summaria MD2, Azeem Latib MD3, Maria De Vita MD, PhD4, Cecilia Fantoni MD5, Stefano Benedetto MD6, Maurizio Turturo MD7, Claudio Larosa MD8, Alessandro Manzoli MD9 andCarlo Trani MD1

Aim: To assess the “real world” clinical outcome of patients with bifurcated lesions undergoing percutaneous coronary intervention with implantation of second and third generations of zotarolimus-eluting stent.

01 enero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions

Nagendra R. Pokala BS, Rohan V. Menon BS, Siddharth M. Patel BS, George Christopoulos MD, Georgios E. Christakopoulos MD, Anna P. Kotsia MD, Bavana V. Rangan BDS, MPH, Michele Roesle RN, Shuaib Abdullah MD, Jerrold Grodin MD, Dharam J. Kumbhani MD, SM, MRCP, Jeffrey Hastings MD, Subhash Banerjee MD andEmmanouil S. Brilakis MD, PhD*

Background: As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs.

01 enero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. One-year clinical outcomes after sirolimus-eluting coronary stent implantation in diabetics enrolled in the worldwide e-SELECT registry

Antonio L. Bartorelli MD1,*, Gabriele Egidy Assenza MD1, Alexandre Abizaid MD2, Adrian Banning MD3, Vladimír Džavík MD4, Stephen Ellis MD5, Runlin Gao MD6, David Holmes MD7, Myung Ho Jeong MD8, Victor Legrand MD9, Franz-Josef Neumann MD10, Christian Spaulding MD11, Stephen G. Worthley MD12, Philip Urban MD13 andfor the e-SELECT Investigators†

Background: Diabetes mellitus has worse outcome after percutaneous coronary intervention.